# Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

> **NCT07691593** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changhai Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** HRS-4642+NALIRIFOX
- **DRUG:** HRS-4642+NALIRIFOX+Adebrelimab
- **DRUG:** HRS-4642+NALIRIFOX+Adebrelimab

## Key facts

- **NCT ID:** NCT07691593
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691593, "Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*